AtaiBeckley Sets Q2 2026 Phase 3 Launch for MDMA Depression Therapy
AtaiBeckley, a joint venture of atai life sciences and Beckley Psytech, plans to launch a Phase 3 study of its MDMA-assisted therapy for treatment-resistant depression in Q2 2026 after positive Phase 2 results. The multicenter trial will span sites in North America and Europe, marking a critical milestone in the company’s psychedelic mental health pipeline.
1. Q2 2026 Phase 3 Launch
AtaiBeckley, the joint venture between atai life sciences and Beckley Psytech, aims to initiate its pivotal Phase 3 clinical study of MDMA-assisted therapy in Q2 2026. This follows completion of Phase 2 trials demonstrating significant symptom reduction in treatment-resistant depression cohorts.
2. Study Design and Scope
The multicenter, randomized trial will recruit about 200 adult patients across sites in North America and Europe. It will assess changes in standardized depression scale scores and monitor safety throughout the treatment protocol.
3. Pipeline and Strategic Impact
Advancing to Phase 3 validates AtaiBeckley’s psychedelic-assisted approach and may attract new licensing or partnership opportunities. Positive outcomes could support future regulatory submissions and pave the way for commercial development in key markets.